Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2014 Apr 22;9(4):e95603. doi: 10.1371/journal.pone.0095603

National Profile and Treatment Outcomes of Patients with Extrapulmonary Tuberculosis in Bénin

Serge Ade 1,*, Anthony D Harries 2,3, Arnaud Trébucq 2, Gabriel Ade 1, Gildas Agodokpessi 1, Christine Adjonou 1, Sophie Azon 1, Sévérin Anagonou 1
Editor: Anthony WI Lo4
PMCID: PMC3995824  PMID: 24755603

Abstract

Background

In sub-Saharan Africa, there is a dearth of published literature on extrapulmonary tuberculosis (EPTB).

Objective

To describe demographic, diagnostic and HIV-status characteristics of patients with EPTB in Bénin, their treatment outcomes, and among those who completed their treatment in the Centre National Hospitalier de Pneumo-Phtisiologie (CNHP-P), the proportion whose bodyweight increased during treatment.

Material and Findings

This was a retrospective cohort study with comparisons made between EPTB and new smear-positive pulmonary tuberculosis (NPTB) patients diagnosed in the country from January to December 2011. There were 383 EPTB patients (9% of all TB cases) with a mean age of 35 years, male/female ratio of 1.3 and important regional variation. There were significantly more females (p = 0.001), children <15years (p<0.001) and HIV-positive patients (p = 0.005) with EPTB compared with NPTB. Pleural effusion, spinal and lymph node tuberculosis accounted for 66% of all EPTB. Children <15 years represented 16% of cases, with lymph node disease being most common among them (p<0.001). Of 130 EPTB patients registered in CNHP-P, 7% had a confirmed bacteriological/histological diagnosis. There were 331 (86%) patients who successfully completed treatment. More patients with EPTB were lost-to-follow-up compared with NPTB (p<0.001) with all these patients from one region. The best treatment completion rates were in children <15 years (OR:3.5, 95%CI:1.0–14.8) while patients with pleural effusion and ascites had the worst outcomes. Of 72 HIV-coinfected patients, 88% were on antiretroviral therapy (ART). HIV-positive status was associated with poor outcomes while those on ART fared better. In the CNHP-P, more than 80% who completed their treatment showed an increase in bodyweight and this was more evident in HIV-positive compared with HIV-negative patients (p = 0.03).

Conclusion

Patients with EPTB generally do well in Bénin, although the TB Programme would benefit through more attention to accurate diagnosis and earlier start of ART in HIV-infected patients.

Introduction

Patients with extrapulmonary tuberculosis (EPTB), i.e., tuberculosis (TB) without associated lung involvement, usually receive less priority in national TB Programmes. However, in many countries, their numbers remain either stable or are increasing while numbers of patients with pulmonary disease are decreasing [1]. In populations with a low prevalence of HIV infection, these patients usually represent 15% to 20% of all TB cases. However, this proportion is thought to be higher in populations with a high prevalence of HIV infection [2], the latter mostly occurring in sub-Saharan Africa.

Confirmation of the diagnosis of EPTB, as recommended by the World Health Organization (WHO) [3], is not easy. Diagnosis in many low income countries is often based on presumptive and circumstantial evidence, with the consequence of a possible misdiagnosis [4].

In Bénin, information is limited about this type of TB, especially with regard to epidemiological characteristics and the most predominant forms of EPTB. Furthermore, the treatment outcomes of patients with EPTB are analyzed in the routine programme together with those of patients with smear-negative pulmonary tuberculosis, the latter in a recent study showing higher rates of unsuccessful treatment compared with new smear-positive pulmonary tuberculosis (NPTB) [5]. These treatment outcomes are usually reported quarterly, using standard classifications; and a “treatment completion” is considered a successful outcome [3]. However, treatment can be completed without improvement of the patient’s health condition, particularly if the diagnosis of EPTB is wrong. The disappearance of initial symptoms along with weight gain in patients who have completed treatment might be a better gauge of successful treatment.

In this study, we aimed to describe the pattern of disease in patients registered as EPTB, their treatment outcomes and among those who completed their treatment in the Centre National Hospitalier de Pneumo-Phtisiologie (CNHP-P), the proportion whose weight increased during the course of treatment. Specific objectives were to determine in Bénin for 2011: i) the number (and proportion) of patients recorded as EPTB and NPTB among all TB cases, ii) demographic, clinical characteristics and HIV-status of patients with EPTB and NPTB, iii) treatment outcomes of patients with EPTB and NPTB and the influence of HIV-infection and antiretroviral therapy and iv) the proportion who increased in weight among those who completed their treatment in the CNHP-P.

Materials and Methods

Ethics Statements

This study was approved by “Ethics Advisory Group” of the International Union against Tuberculosis and Lung Disease, Paris, France and “Bénin TB Control Programme Coordination”. Because of its retrospective nature, the local Ethics Committee approval (“Comité National d’Ethique pour la Recherche en Santé”) was not required according to the country’s recommendations.

This study uses already collected data, and written informed consent -given by participants was not possible to obtain. Patient records/Information was collected anonymously. Each participant of this study was attributed a unique identifier number, in order to compare data files that have been double entered. After checking and cleaning the database, the unique identifier numbers have been removed and participants were de-identified prior to analysis. There was no way to recognize them. All databases were kept confidential and have been protected with a password, with only access by authorized persons.

Study Design

This was a retrospective cohort study of all patients recorded as EPTB and NPTB between 1st January and 31st December 2011 in Bénin.

Setting – General and Study Site, Including TB Programme

Bénin is a West-African country with a population of 9 million and a HIV prevalence rate of 1.1% [6]. Seven to 10% of the 4000 TB patients registered each year have EPTB. There is a national TB Programme which follows the DOTS strategy and uses recognised international criteria for the diagnosis and treatment of TB patients [7]. Diagnosis, registration and care are decentralised to 57 Basic Management Units in the country. Of them, the largest is the CNHP-P of Cotonou, the economic capital. It houses the Mycobacteria Reference Laboratory where culture and molecular diagnostics can be performed for the whole the country.

Diagnosis and management of NPTB and EPTB in the Bénin TB control Programme

Pulmonary TB diagnosis is made with respect of WHO recommandations [2]. A person who coughs more than 3 weeks is regarded as having presumptive pulmonary tuberculosis. He/she is requested to provide two sputum samples for acid-fast bacilli microscopy. Sputum samples are examined using either auramine-phenol staining and fluorescence microscopy or Ziehl-Neelsen staining with light microscopy. Patients with at least one sputum smear positive for acid-fast bacilli and who have never been previously treated for TB (or less than one month) are registered as NPTB.

A patient is considered as having presumptive EPTB if he/she has symptoms suggestive of TB related to an extrapulmonary site, with a decision then made by a medical doctor to treat with a full course of anti-tuberculosis treatment. Usually, because of difficulties in accessing and obtaining specimens from different biological sites, TB treatment is started based on symptoms and other circumstantial evidence that includes laboratory investigations and radiographic abnormalities. Whenever possible, specimens collected should be submitted for bacteriological investigation (direct microscopy examination or standard culture, or molecular tests). Rarely, these specimens are also analysed in histology laboratories. In terms of registration, for patients who have TB in both pulmonary and extrapulmonary sites, they are classified as having “pulmonary TB”. For patients with TB in several extrapulmonary sites (e.g., lymph nodes and pleural effusion), they are registered according to the most severe form of disease.

All NPTB and EPTB cases are treated with the same standardized first-line anti-tuberculosis regimen. Patients receive daily rifampicin, pyrazinamide, isoniazid and ethambutol for 2 months (initial phase) followed by daily rifampicin and isoniazid for 4 months (continuation phase). Contrary to the treatment of NPTB, EPTB treatment is not directly observed during the intensive phase and anti-tuberculosis drugs are given every two weeks for self administration. Treatment is free and is only provided by the Programme for all TB patients. TB drugs are not available in private pharmacies in the city or country. While sputum microscopy examination is performed during follow-up of NPTB patients, those with EPTB are monitored clinically and in particular body weight is measured and recorded during treatment on personal treatment cards (at two, five and six months).

Standardized treatment outcomes are monitored through the use of treatment cards and registers, and number of cases and outcomes are quarterly reported.

TB/HIV co-infection management

Every patient who is diagnosed with TB (including EPTB) is systematically offered an HIV test using rapid tests and following national guidelines [8]. Those who are found to be HIV positive receive in addition cotrimoxazole. Since 2011 and according to recent WHO guidelines, all TB cases (including EPTB) are eligible for antiretroviral therapy (ART) [9]. The first line ART regimen is efavirenz and two other drugs, zidovudine and lamivudine. If there is anemia (Haemoglobin<7 g/dl) or a low platelet count (<75000/l) zidovudine is replaced by stavudine. Cotrimoxazole and ART are provided free of charge.

Study Patients

All patients recorded as EPTB and NPTB between 1st January and 31st December 2011 in Bénin were included in the study.

Data Variables, Sources of Data and Data Collection

Variables for NPTB and EPTB patients included: sex, age, residence by region, HIV-status (positive, negative, unknown), cotrimoxazole and ART administration, treatment outcomes (completion, death, loss-to-follow-up, not evaluated). Variables for EPTB patients included in addition:- sites of disease (pleural effusion, spinal, lymph node, bone or joint, ascites, other and not recorded) and weight change during treatment for patients managed in the CNHP-P. Individual data for EPTB patients were collected from TB registers, laboratory TB registers, treatment cards and TB medical personal files into a standardized paper-based study questionnaire. For NPTB patients, data were collected from quarterly and annual reports.

Analysis and Statistics

Data were double entered into an electronic file (EpiData3.1, EpiData Association, Odense, Denmark). Data were analyzed by frequencies and percentages. Comparisons were made between groups using the chi-square test, odds ratios (OR) and 95% confidence intervals (95% CI) as appropriate. Levels of significance were set at 5%.

Results

Numbers, Epidemiological and Diagnostic Characteristics of TB Patients

The number and proportion of patients with EPTB and NPTB diagnosed in the same time period are shown in Table 1 . Overall, EPTB patients represented 9% of all TB cases (mean age: 34.5 years, male/female ratio: 1.3), with a large variation between regions from 23% in Borgou (North of the country) to 5% in Ouémé (South of the country). All patients were new cases. Demographic characteristics and HIV-status of patients with EPTB and NPTB are shown in Table 2 . There were significantly more females (p = 0.001), children under 15 years (p<0.001) and HIV-positive patients (p = 0.005) diagnosed with EPTB compared with NPTB.

Table 1. Patients with extrapulmonary tuberculosis and new smear-positive pulmonary tuberculosis registered in Bénin and the different regions of the country in 2011.

Place All TB** EPTB (%*) NPTB (%)
Bénin 4320 383 (8.9) 3331 (77.1)
Regions Atacora 251 18 (7.2) 189 (75.3)
Borgou 367 58 (23.1) 255 (69.5)
Zou 567 70 (12.3) 442 (78)
Atlantique 1646 146 (8.9) 1226 (74.5)
Mono 664 51 (7.7) 534 (80.4)
Ouémé 825 40 (4.8) 685 (83)

Note: EPTB: Extrapulmonary tuberculosis; NPTB: New smear-positive pulmonary tuberculosis; TB: Tuberculosis.

* The percentage is calculated from the total number of TB cases diagnosed in each region.

** All TB cases include all patients with new and retreatment TB, irrespective of the site of tuberculosis.

Table 2. Demographic characteristics and HIV-status in patients with extrapulmonary tuberculosis and new smear-positive pulmonary tuberculosis, Bénin, 2011.

Characteristics EPTB (%) NPTB (%) p(value)
Sex Male 216 (56.4) 2158 (64.8) 0.001
Female 167 (43.6) 1173 (35.2) 0.001
Age (years) 00–14 62 (16.2) 62 (1.9) <0.001
15–24 62 (16.2) 608 (18.3) NS
25–34 75 (19.6) 1035 (31.1) <0.001
35–44 64 (16.7) 743 (22.3) 0.01
45–54 58 (15.1) 472 (14.2) NS
55–64 36 (9.4) 252 (7.6) NS
≥65 26 (6.8) 159 (4.8) NS
HIV-status Positive 72 (18.8) 449 (13.5) 0.005
Negative or unknown 312 (81.5) 2882 (86.5) 0.005
Total 383 3331

Note: EPTB: Extrapulmonary tuberculosis, NPTB: New smear positive pulmonary tuberculosis; TB: Tuberculosis.

The different sites of EPTB are presented in Table 3 . Pleural effusion, spinal disease and lymph node disease accounted for 66% of all EPTB cases. Demographic characteristics and HIV-status in relation to the different sites of EPTB are shown in Table 4 . There was no association between gender and different types of EPTB. Children (under 15 years) represented 16% (62/383) of all EPTB cases diagnosed. Lymph node TB was more common in children than adults (p<0.001) while TB pleural effusion was more common in adults (p<0.001). Otherwise, there were no significant associations between age and other sites of EPTB. Compared with other regions, there was significantly more lymph node TB (OR: 2.6, 95%CI: 1.4–4.7, p = 0.001) and bone or joint TB (OR: 4.9, 95%CI: 2.1–11.6, p<0.001) in Zou while there was significantly more TB pleural effusion in the Atlantique region. TB pleural effusion was significantly more common in HIV-positive patients compared with HIV-negative patients (p<0.001).

Table 3. Different sites of extrapulmonary tuberculosis in Bénin, 2011.

Sites n (%)
Pleural effusion 94 (24.5)
Spine 82 (21.4)
Lymph node 77 (20.1)
Bone and Joint 29 (7.6)
Ascites 15 (3.9)
Other * 17 (4.4)
Not recorded 69 (18)
Total 383

Note: * Others include pericardial TB (n = 10), cerebral TB (n = 1), meningeal TB (n = 1), female genital TB (n = 1), male genital TB (n = 3), skin TB (n = 1).

TB: Tuberculosis.

Table 4. Epidemiological characteristics and HIV-status in relation to the different sites of extrapulmonary tuberculosis, Bénin, 2011.

Characteristics Total Pleural effusion Spine Lymph node Bone/Joint Ascites Other * Not recorded
Sex Male 216 58 (26.9) 39 (18.1) 42 (19.4) 16 (7.4) 8 (3.7) 12 (5.6) 41 (19)
Female 167 36 (21.6) 43 (25.7) 35 (21) 13 (7.8) 7 (4.2) 5 (3) 28 (16.8)
Age (Years) <15 62 3 (4.8) 12 (19.4) 24 (38.7) 8 (12.9) 2 (3.2) 1 (1.6) 12 (19.4)
≥15 321 91 (28.3) 70 (21.8) 53 (16.5) 21 (6.5) 13 (4) 16 (5) 57 (17.8)
Region Atacora 18 1 (5.6) 3 (16.7) 5 (27.8) 0 (0) 1 (5.6) 1 (5.6) 7 (38.9)
Borgou 58 10 (17.2) 19 (32.8) 10 (17.2) 8 (13.8) 2 (3.4) 2 (3.4) 7 (12.1)
Zou 70 8 (11.4) 18 (25.7) 24 (34.3) 14 (20) 1 (1.4) 0 (0) 5 (7.1)
Mono 51 3 (5.9) 9 (17.6) 3 (5.9) 3 (5.9) 2 (3.9) 1 (2) 30 (58.8)
Atlantique 146 69 (47.3) 27 (18.5) 23 (15.8) 1 (0.7) 8 (5.5) 12 (8.2) 6 (4.1)
Ouémé 40 3 (7.5) 6 (15) 12 (30) 3 (7.5) 1 (2.5) 1 (2.5) 14 (35)
HIV-Status Positive 72 29 (40.3) 4 (5.6) 15 (20.8) 0 (0) 5 (6.9) 3 (4.2) 16 (22.2)
Negative 306 65 (21.2) 74 (24.2) 61 (19.9) 29 (100) 10 (3.3) 14 (4.6) 53 (17.3)
Unknown 5 0 (0) 4 (80) 1 (20) 0 (0) 0 (0) 0 (0) 0 (0)
Total 383 94 82 77 29 15 17 69

Note: * Others include pericardial TB (n = 10), cerebral TB (n = 1), meningeal TB (n = 1), female genital track TB (n = 1), male genital track TB (n = 3), skin TB (n = 1).

TB: Tuberculosis.

The only health facility where confirmation of diagnostic has been assessed was CNHP-P. Of 130 EPTB patients registered and followed-up in this centre, the diagnosis was confirmed for 9 cases (7%): 2 with positive Mycobacterium tuberculosis culture and direct smear examination, 1 with positive culture alone, 1 with positive direct smear examination alone and 5 with histology showing tuberculous granuloma. For aspirates of pleural or peritoneal fluid, measurements of protein concentration and cytological analysis were performed for all cases.

Treatment Outcomes

Treatment outcomes of patients with EPTB and NPTB are presented in Table 5 . Overall, 86% of patients successfully completed treatment. There were significantly more patients with EPTB who were lost-to-follow-up compared with NPTB (p<0.001). Treatment outcomes in relation to demographic characteristics, sites of disease, HIV-status and ART administration to co-infected patients are shown in Table 6 . No association was found between gender and treatment outcomes. However, treatment success was higher in children aged <15 years (OR: 3.5, 95%CI: 1.0–14.8, p: 0.02). All patients who were lost-to-follow-up during treatment were from the Atlantique region and patients with pleural effusion or ascites had the worst completion rates.

Table 5. Treatment outcomes of patients with extrapulmonary tuberculosis and new smear-positive pulmonary tuberculosis in Bénin, 2011.

Treatment outcomes EPTB (%) NPTB (%) p (value)
Successful completion 331 (86.4) 2988 (89.9) ** 0.03
Failure 0 (0) 99 (3) <001
Death 32 (8.4) 196 (5.9) NS
Loss-to-follow up 15 (3.9) 27 (0.9) <0.001
Not evaluated 5 (1.3) 14 (0.4) 0.04
Total evaluated 383 3324 *

Note: EPTB: Extrapulmonary tuberculosis; NPTB: New smear positive pulmonary tuberculosis.

* 7 patients of the 3331 were wrongly registered as new smear-positive TB and were removed from the cohort analysis one year later.

** 2800 of the 2988 patients were cured with negative sputum smear examination for acid-fast bacilli.

Table 6. Treatment outcomes of patients with extrapulmonary tuberculosis in relation to demographic characteristics, regions, HIV status and ART administration in those with HIV coinfection, Bénin, 2011.

Characteristics Total Completion Death Loss-to-follow-up Not evaluated
Sex Male 216 183 (84.7) 17 (7.9) 11 (5.1) 5 (2.3)
Female 167 148 (88.6) 15 (9) 4 (2.4) 0 (0)
Age (years) <15 62 59 (95.2) 2 (3.2) 1 (1.6) 0 (0)
≥15 321 272 (84.7) 30 (9.3) 14 (4.4) 5 (1.6)
Region Atacora 18 17 (94.4) 1 (5.6) 0 (0) 0
Borgou 58 47 (81) 10 (17.2) 0 (0) 1 (1.7)
Zou 70 67 (95.7) 2 (2.9) 0 (0) 1 (1.4)
Mono 51 47 (92.2) 4 (7.8) 0 (0) 0 (0)
Atlantique 146 114 (78.1) 14 (9.6) 15 (10.3) 3 (2.1)
Ouémé 40 39 (97.5) 1 (2.5) 0 (0) 0 (0)
Site Pleurisy 94 73 (77.7) 11 (11.7) 7 (7.4) 3 (3.2)
Spine 82 75 (91.5) 4 (4.9) 1 (1.2) 2 (2.4)
Lymph node 77 70 (90.9) 4 (5.2) 3 (3.9) 0 (0)
Bone and Joints 29 27 (93.1) 2 (6.9) 0 (0) 0 (0)
Ascites 15 10 (66.7) 4 (26.7) 1 (6.7) 0 (0)
Other* 17 14 (82.4) 1 (5.9) 2 (11.8) 0 (0)
Not recorded 69 62 (89.9) 6 (8.7) 1 (1.4) 0 (0)
HIV-Status Negative 306 270 (88.2) 21 (6.9) 11 (3.6) 4 (1.3)
HIV positive on ART 63 52 (82.5) 9 (14.3) 1 (1.6) 1 (1.6)
HIV positive not on ART 9 4 (44.4) 2 (22.2) 3 (33.3) 0 (0)
Unknown 5 5 (100) 0 (0) 0 (0) 0 (0)
Total 383 331 32 15 5

Note: * Others include pericardial TB (n = 10), cerebral TB (n = 1), meningeal TB (n = 1), female genital track TB (n = 1), male genital track TB (n = 3), skin TB (n = 1).

TB: Tuberculosis; ART: Antiretroviral therapy.

Finally, of 72 HIV-TB co-infected patients, 99% received cotrimoxazole and 88% were given ART. HIV-positive patients were at higher risk of death than HIV-negative patients during treatment (OR: 2.5, 95%CI: 1.0–5.7, p: 0.02). In HIV-positive patients, those on ART had much better outcomes than those not on ART (82.5% versus 44.4%, p = 0.03). The concomitant administration of ART was also associated with a lower loss-to-follow-up rate (OR: 31, 95%CI: 2.2–922, p: 0.005). There were no other significant differences.

Weight Variation during Treatment

The change in body weight among patients who completed their treatment in relation to HIV-status in the CNHP-P, the largest basic management unit in Bénin, is shown in Table 7 . Up to 80% of patients who successfully completed treatment showed an increase in body weight, and this was more apparent among HIV-positive than HIV-negative patients (p = 0.03).

Table 7. Treatment completion and change in weight in HIV-positive and HIV-negative patients with extrapulmonary tuberculosis treated in the Centre National Hospitalier de Pneumo-Phtisiologie, Bénin.

Characteristics All patients HIV-negative HIV-positive p (value)
Extrapulmonary tuberculosis 129 95 34
Treatment Completion n (%*) 101 (78.3) 74 (77.9) 26 (76.5) 0.86
Increase in Weight n (%**) 82 (81.2) 60 (81.1) 21 (80.8) 0.83
Mean increase in weight (Kg) [95%CI] 5.8 [4.9–6.6] 5.21 [4.2–6.2] 7.3 [5.7–8.9] 0.03

Note:

* The percentage was calculated from the EPTB cases diagnosed.

** The percentage is calculated from the total number of patients who completed their treatment.

95CI = 95 Confidence Interval.

Discussion

This is the first study in Bénin to describe the epidemiological and diagnostic characteristics and treatment outcomes of EPTB patients. Patients with EPTB constituted less than 10% of all notifications, with some parts of the country showing higher prevalence than others. EPTB appeared to be more common in females, children under the age of 15 years and in those who were HIV-positive. Predominant sites of disease were pleural, spinal and lymph node, with TB lymph node disease being more common in children and pleural effusion being more common in adults, especially those HIV-positive. Diagnostic confirmation was rare even in the largest basic management unit in the country.

Successful treatment completion was good especially in children, although there was a higher rate of loss-to-follow-up when compared with patients who had NPTB. Interestingly, all patients lost to follow-up were from a specific region of Bénin. Patients with pleural effusion and ascites had the worst treatment completion rates. Patients with HIV-associated TB remained at higher risk of death compared with those who did not have HIV-infection, although those on ART fared much better. Finally, in CNHP-P where weight during the treatment has been collected, there was a significant weight gain amongst those who completed treatment, with the change in weight being more evident in patients who were HIV-positive compared with those who were not HIV-infected.

The strengths of this study were that it involved the whole population and it was therefore nationally representative of the epidemiology of EPTB in Bénin. There was no need for any sampling framework. In addition, basic management units are regularly supervised every three months by the TB control Programme coordination, and during these supervisory visits, quarterly reports and patients’ personal data are systematically reviewed and if necessary, corrections are made. Limitations related to the operational nature of the study which used already collected data from registers, medical files and quarterly reports which are difficult to validate when conducting a retrospective record review. In spite of regular supervision, some errors could also remain in the consulted documents.

There were important variations in the proportion of EPTB patients in the different regions of the country; and this could be related to the implication of medical doctors in the diagnosis of this form of TB. In Borgou region, where the highest proportion of EPTB cases was reported from, the large majority of these patients were diagnosed in two well frequented hospitals because of their good reputation (a confessional centre and a teaching hospital).

The proportion of patients diagnosed with EPTB in Bénin was lower than that reported from other parts of world [1], [10][15], and few diagnoses were confirmed. Lack of appropriate and specific diagnosis in EPTB in sub-Saharan Africa remains a continuing source of debate [4]. There are recommendations that the diagnosis of EPTB should be based on at least one specimen with confirmed Mycobacterium tuberculosis (using microscopy examination, culture or rapid molecular testing), histological or strong clinical evidence consistent with active EPTB, followed by a clinician decision to treat with a full course of tuberculosis chemotherapy [3].

However, in resource-poor countries like Bénin, following these recommendations is difficult. Obtaining the diagnosis is difficult for several reasons, such as lack of specialised physicians, microbiologists and pathologists, weak laboratory infrastructure and poor access to radiography and other more sophisticated imaging technologies such as ultrasound and computerised tomography scans.

The finding of females, children and HIV-positive patients having a higher prevalence of EPTB is in line with reports from other countries [1], [12], [16], [17]. For children, the predominant site of TB reported in the literature is usually lymph node disease [1], although in adults a wide variety of patterns is reported from other countries which may depend to a large extent on resources available for diagnosis [16], [18][25]. In Bénin, we found few patients with TB meningitis, while the proportion diagnosed in others studies has been higher [23], [24]. This may be due to good coverage of BCG immunization in Bénin and also the difficulties in establishing the diagnosis in this type of disease [22], [26], [27].

Although successful treatment completion was reasonable, this could be improved by reducing the losses-to-follow-up, especially in Atlantique region, where Cotonou, the economic capital city of the country, is located. One of the reasons for patients being lost-to-follow-up may be misdiagnosis, and this has been found in other parts of Africa. Patients with other pathology such as lung cancer, mesothelioma or systemic disease may be wrongly treated with anti-tuberculosis drugs without improvement, persuading them to seek alternative opinions and stopping treatment. Another reason is that some patients reported as lost-to-follow-up may have died, and this has also been found in other studies [28]. Finally more attention needs to be paid to accurate diagnosis of patients with pleural effusion and ascites, the latter especially having a wide differential diagnosis that includes chronic liver disease.

HIV-positive patients with EPTB were at higher risk of death than HIV-negative patients, despite good coverage with ART. Often, HIV-infected patients with EPTB present with advanced immune suppression with CD4 counts <200 cells/µl, and hence their classification as a WHO Stage 4 AIDS defining disease. As a result, patients can also be affected by other opportunistic diseases that can result in death [29], [30]. The time of start of ART in relation to start of anti-TB treatment is an important factor that determines mortality, and late initiation of ART is associated with increased case fatality [9]. A weakness of this study was the lack of information about when ART was started.

Finally, we assessed whether patients who completed treatment increased their weight, the latter adding to the evidence to support a successful treatment completion. The large majority of patients who completed their treatment showed an increase in body weight, especially in HIV-positive patients, and this has been found elsewhere. As recommended in guidelines, weight should be regularly measured during the course of treatment [4], [31].

The findings of this study have several implications for the Bénin TB control Programme. First, there is a need to improve the diagnosis of EPTB in the country and to perform appropriate examinations when needed such as mycobacterial culture on tissue and other specimens. The introduction of rapid molecular tests such as Xpert MTB/RIF should be considered especially for the more difficult-to-diagnose cases of EPTB [32], [33]. Second, the follow-up of patients during treatment must improve especially in the Atlantique region where there was high loss-to-follow-up. Third, more attention needs to be paid to getting HIV-infected patients on to ART as soon as possible and to ensure that the time of start of ART in relation to start of anti-TB treatment is well documented.

Conclusion

The study has shown that the proportion of patients diagnosed and registered with EPTB was low and below 10%. Treatment outcomes of EPTB cases were satisfactory, although the high loss-to-follow-up in the Atlantique region of the country needs to be rectified. The TB control Programme in Bénin would benefit through more attention to accurate diagnosis of EPTB and earlier start of ART in HIV-infected patients.

Acknowledgments

The authors thank workers in the 57 basic management units in the National TB Programme of Bénin for their involvement in the fight against tuberculosis. The authors thank the International Union Against Tuberculosis and Lung Disease (The Union), Paris, France, for technical support. Serge Ade is a Union Operational Research Fellow.

Funding Statement

The International Union Against Tuberculosis and Lung Disease (The Union), Paris, France, financially supports Serge Ade through a Union Operational Research Fellowship. Funding was from an anonymous donor and the Department for International Development, UK. Additional financial support for this study was provided by the «Service de la santé publique, Lausanne de l’Etat de Vaud, Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Sandgren A, Hollo V, van der Werf MJ (2013) Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011. Euro Surveill 18(12): pii = 20431. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20431. Accessed 2013 Dec 9. [PubMed]
  • 2.Tuberculosis Coalition for Technical Assistance (2009) International Standards for Tuberculosis Care (ISTC), 2nd edition. Tuberculosis Coalition for Technical Assistance, The Hague. Available: http//www.istcweb.org. Accessed 12Th December 2013.
  • 3.WHO (2009) Treatment of tuberculosis Guidelines 4Th edition. WHO/HTM/TB/2009.420.
  • 4. Harries AD, Hargreaves NJ, Kwanjana JH, Salaniponi FM (2003) The diagnosis of extra-pulmonary tuberculosis in Malawi. Trop Doct 33: 7–11. [DOI] [PubMed] [Google Scholar]
  • 5. Ade S, Harries AD, Trébucq A, Hinderaker SG, Ade G, et al. (2013) National profile and treatment outcomes of adult smear-negative pulmonary tuberculosis patients in Benin. Trans R Soc Trop Med Hyg 107: 783–788 10.1093/trstmh/trt092 [DOI] [PubMed] [Google Scholar]
  • 6.UNAIDS (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. UNAIDS: Geneva, Switzerland. UNAIDS.
  • 7. WHO IUATLD (2001) KNCV (2001) Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 5(3): 213–215. [PubMed] [Google Scholar]
  • 8.National Tuberculosis Control Programme (2009) National tuberculosis guide. Cotonou, Benin: NTP. Available: http://www.pnt-benin.bj/spip.php?article48. Accessed 2013 Dec 9.
  • 9.WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Geneva, Switzerland. World Health Organization. [PubMed]
  • 10. Rock RB, Sutherland WM, Baker C, Williams DN (2006) Extra-pulmonary tuberculosis among Somalis in Minnesota. Emerg Infect Dis 12: 1434–1436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.te Beek LAM, van der Werf MJ, Richter C Borgdorff MW (2006) Extrapulmonary tuberculosis by nationality, the Netherlands, 1993–2001. Emerg Infect Dis 12: 1375–1382. Available: http//www.cdc.gov/eid. Accessed 9th December 2013. [DOI] [PMC free article] [PubMed]
  • 12. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR (2009) Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis 49: 1350–1357. [DOI] [PubMed] [Google Scholar]
  • 13. Kruijshaar ME, Abubakar I (2009) Increase in extrapulmonary tuberculosis in England and Wales 1999–2006. Thorax 64: 1090–1095 10.1136/thx.2009.118133 [DOI] [PubMed] [Google Scholar]
  • 14. Garcia-Rodriguez JF, Alvarez-Diaz H, Lorenzo-Garcia MV, Marino-Callejo A, Fernandez-Rial A, et al. (2011) Extrapulmonary tuberculosis: epidemiology and risk factors. Enferm Infecc Microbiol Clin 29(7): 502–509. [DOI] [PubMed] [Google Scholar]
  • 15. Mazza-Stalder J, Nicod L, Janssens JP (2012) Extrapulmonary tuberculosis. Rev Mal Respir 29(4): 566–578 10.1016/j.rmr.2011.05.021 [DOI] [PubMed] [Google Scholar]
  • 16. Lin JN, Lai CH, Chen YH, Lee SSJ, Tsai SS, et al. (2009) Risk factors for extra-pulmonary tuberculosis compared to pulmonary tuberculosis. Int J Tuberc Lung Dis 13(5): 620–625. [PubMed] [Google Scholar]
  • 17. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, et al. (2004) Identification of Risk Factors for extrapulmonary tuberculosis. Clin Infect Dis 38: 199–205. [DOI] [PubMed] [Google Scholar]
  • 18. Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, et al. (2012) Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis 55(1): 75–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gunal S, Yang Z, Agarwal M, Koroglu M, Arici ZK, et al. (2011) Demographic and microbial characteristics of extrapulmonary tuberculosis cases diagnosed in Malatya, Turkey, 2001–2007. BMC Public Health 11: 154. Available: http://www.biomedcentral.com/1471-2458/11/154. Accessed 2013 Dec 9. [DOI] [PMC free article] [PubMed]
  • 20. Gonzalez OY, Adams G, Teeter LD, Bui TT, Musser JM, et al. (2003) Extrapulmonary manifestations in a large metropolitan area with a low incidence of tuberculosis. Int J Tuberc Lung Dis 7: 1178–1185. [PubMed] [Google Scholar]
  • 21. Özvaran MK, Baran R, Tor M, Dilek I, Demiryontar D, et al. (2007) Extrapulmonary tuberculosis in non-human immunodeficiency virus-infected adults in an endemic region. Ann Thorac Med 2(3): 118–121 10.4103/1817-737.33700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Ozbay B, Uzun K (2002) Extrapulmonary tuberculosis in high prevalence of tuberculosis and low prevalence of HIV. Clin Chest Med 23(2): 351–354. [DOI] [PubMed] [Google Scholar]
  • 23. Kourbatova EV, Leonard MK Jr, Romero J, Kraft C, del Rio C, et al. (2006) Risk factors for mortality among patients with extrapulmonary tuberculosis at an academic inner-city hospital in the US. Eur J Epidemiol 21(9): 715–721. [DOI] [PubMed] [Google Scholar]
  • 24. Savina TA, Suprun TIu (2007) The pattern of extrapulmonary tuberculosis according to the materials of Saint Petersburg City Tuberculosis Hospital Two and the problems in delivery of health care. Probl Tuberk Bolezn Legk (7): 12–15. [PubMed] [Google Scholar]
  • 25. Jamtsho T, Harries AD, Malhotra S, Wangchuk D, Dophu U, et al. (2013) The burden and treatment outcomes of extra-pulmonary tuberculosis in Bhutan. PHA 3(1): 38–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ministère de la Santé (2012) Annuaire des statistiques sanitaires de l’année 2012. Cotonou, Bénin: Ministère de la Santé. [French] Available: http://www.beninsante.bj/spip.php?article66. Accessed 2013 Dec 12.
  • 27. Trunz BB, Fine PEM, Dye C (2006) Effect of BCG vaccination on childhood tuberculous meningitis and military tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367: 1173–1180. [DOI] [PubMed] [Google Scholar]
  • 28. Kruyt ML, Kruyt ND, Boeree MJ, Harries AD, Salaniponi FM, et al. (1999) True status of smear-positive pulmonary tuberculosis defaulters in Malawi. Bull World Health Organ 77(5): 386–391. [PMC free article] [PubMed] [Google Scholar]
  • 29. Kwan CK, Ernst JD (2011) HIV and Tuberculosis: a deadly human syndemic. Clin Microbiol Rev 24(2): 351 10.1128/CMR.00042-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatittham W, et al. (2009) HIV-associated extrapulmonary tuberculosis in Thailand: Epidemiology and risk factors for death. Int J Infect Diseases 13: 722–729. [DOI] [PubMed] [Google Scholar]
  • 31. Bernabe-Ortiz A, Carcamo CP, Sanchez JF, Rios J (2011) Weight variation over time and its association with tuberculosis treatment outcome: A longitudinal analysis. PLoS ONE 6(4): e18474 10.1371/journal.pone.0018474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Lawn SD, Zumla AI (2012) Diagnosis of extrapulmonary tuberculosis using the Xpert MTB/RIF Assay. Expert Rev Anti Infect Ther 10(6): 631–635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Vadwai V, Boehme C, Nabeta P, Shetty A, Alland D, et al. (2011) Xpert MTB/RIF: a new Pillar in diagnosis of extrapulmonary tuberculosis. J Clin Microbiol 49(7): 2540–2545. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES